12/10/2004 (Agence Europe) - Further to the withdrawal from the market of the drug Vioxx by Merck Sharp & Dohme on 30 September, the European Medicines Agency decided on 5 October to re-examine the data on cardiovascular safety for all non-steroidal anti-inflammatories in the coxib family, within the next two weeks.